Patient characteristics by age group and risk group
| . | Enrolled patients . | P* . | Standard-risk patients . | High-risk patients . | Risk unknown . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Age at diagnosis, mo | 0-1 | 1-12 | 0-1 | 1-12 | 0-1 | 1-12 | 0-1 | 1-12 | |
| Total patients | 30 | 452 | 17 | 307 | 12 | 139 | 1 | 6 | |
| Female sex | 17 (57%) | 234 (52%) | .71 | 10 (59%) | 161 (52%) | 6 (50%) | 71 (49%) | 1 | 2 |
| WBC count (cells/L) | .01 | ||||||||
| Less than 100 × 109 | 7 (23%) | 204 (46%) | 7 (41%) | 167 (55%) | 0 | 35 (25%) | 0 | 2 | |
| 100-300 × 109 | 16 (53%) | 123 (27%) | 9 (53%) | 91 (30%) | 6 (50%) | 32 (23%) | 1 | 0 | |
| At least 300 × 109 | 7 (23%) | 121 (27%) | 1 (6%) | 48 (16%) | 6 (50%) | 72 (52%) | 0 | 1 | |
| Not known | 0 | 4 | 0 | 1 | 9 | 0 | 0 | 3 | |
| Immunophenotype | .09 | ||||||||
| B-lineage: CD10 negative | 22 (76%) | 251 (62%) | 14 (88%) | 168 (61%) | 7 (58%) | 80 (63%) | 1 | 3 | |
| B-lineage: CD10 positive | 6 (21%) | 133 (33%) | 2 (13%) | 103 (37%) | 4 (33%) | 29 (23%) | 0 | 1 | |
| B-lineage: CD10 unknown | 1 | 37 | 1 | 25 | 0 | 12 | 0 | 0 | |
| Other | 0 | 21 (5%) | 0 | 5 (2%) | 0 | 16 (11%) | 0 | 0 | |
| AUL | 1 (3%) | 2 (0%) | 0 | 1 (0%) | 1 (8%) | 1 (1%) | 0 | 0 | |
| Not known | 0 | 8 | 0 | 5 | 0 | 1 | 0 | 2 | |
| 11q23 abnormalities (MLL gene status) | .09† | ||||||||
| Not (fully) known | 3 | 83 | 0 | 51 | 3 | 20 | 0 | 2 | |
| MLL germline | 2 (7%) | 80 (22%) | 1 (6%) | 59 (24%) | 1 (11%) | 21 (18%) | 0 | 0 | |
| MLL rearrangement | 25 (93%) | 289 (78%) | 16 (94%) | 187 (76%) | 8 (89%) | 98 (82%) | 1 | 4 | |
| t(4;11) | 12 (48%) | 154 (53%) | 8 (50%) | 101 (54%) | 3 (38%) | 50 (51%) | 1 | 3 | |
| t(9;11) | 1 (4%) | 34 (12%) | 1 (6%) | 25 (13%) | 0 | 8 (8%) | 0 | 1 | |
| t(11;19) | 8 (32%) | 56 (19%) | 5 (31%) | 34 (18%) | 3 (38%) | 22 (22%) | 0 | 0 | |
| Other fusion partner‡ | 2 (8%) | 23 (8%) | 2 (13%) | 12 (6%) | 0 | 11 (11%) | 0 | 0 | |
| Fusion partner undefined | 2 (8%) | 22 (8%) | 0 | 15 (8%) | 2 (25%) | 7 (7%) | 0 | 0 | |
| CNS involvement | .48 | ||||||||
| Yes | 3 (10%) | 41 (11%) | 1 (8%) | 25 (9%) | 1 (13%) | 14 (12%) | 1 | 2 | |
| No | 18 (90%) | 347 (89%) | 11 (92%) | 244 (91%) | 7 (88%) | 102 (88%) | 0 | 1 | |
| Not evaluable or not known | 9 | 64 | 5 | 38 | 4 | 31 | 0 | 3 | |
| Response to 7-day prednisone prophase | .29 | ||||||||
| Good response | 17 (61%) | 301 (70%) | 16 (100%) | 300 (100%) | 1 (8%) | 1 (1%) | 0 | 0 | |
| Poor response | 11 (39%) | 127 (30%) | 0 | 0 | 11 (92%) | 127 (99%) | 0 | 0 | |
| Not evaluable | 0 | 6 | 0 | 2 | 0 | 4 | 0 | 0 | |
| Not known | 2 | 18 | 1 | 5 | 0 | 7 | 1 | 6 | |
| . | Enrolled patients . | P* . | Standard-risk patients . | High-risk patients . | Risk unknown . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Age at diagnosis, mo | 0-1 | 1-12 | 0-1 | 1-12 | 0-1 | 1-12 | 0-1 | 1-12 | |
| Total patients | 30 | 452 | 17 | 307 | 12 | 139 | 1 | 6 | |
| Female sex | 17 (57%) | 234 (52%) | .71 | 10 (59%) | 161 (52%) | 6 (50%) | 71 (49%) | 1 | 2 |
| WBC count (cells/L) | .01 | ||||||||
| Less than 100 × 109 | 7 (23%) | 204 (46%) | 7 (41%) | 167 (55%) | 0 | 35 (25%) | 0 | 2 | |
| 100-300 × 109 | 16 (53%) | 123 (27%) | 9 (53%) | 91 (30%) | 6 (50%) | 32 (23%) | 1 | 0 | |
| At least 300 × 109 | 7 (23%) | 121 (27%) | 1 (6%) | 48 (16%) | 6 (50%) | 72 (52%) | 0 | 1 | |
| Not known | 0 | 4 | 0 | 1 | 9 | 0 | 0 | 3 | |
| Immunophenotype | .09 | ||||||||
| B-lineage: CD10 negative | 22 (76%) | 251 (62%) | 14 (88%) | 168 (61%) | 7 (58%) | 80 (63%) | 1 | 3 | |
| B-lineage: CD10 positive | 6 (21%) | 133 (33%) | 2 (13%) | 103 (37%) | 4 (33%) | 29 (23%) | 0 | 1 | |
| B-lineage: CD10 unknown | 1 | 37 | 1 | 25 | 0 | 12 | 0 | 0 | |
| Other | 0 | 21 (5%) | 0 | 5 (2%) | 0 | 16 (11%) | 0 | 0 | |
| AUL | 1 (3%) | 2 (0%) | 0 | 1 (0%) | 1 (8%) | 1 (1%) | 0 | 0 | |
| Not known | 0 | 8 | 0 | 5 | 0 | 1 | 0 | 2 | |
| 11q23 abnormalities (MLL gene status) | .09† | ||||||||
| Not (fully) known | 3 | 83 | 0 | 51 | 3 | 20 | 0 | 2 | |
| MLL germline | 2 (7%) | 80 (22%) | 1 (6%) | 59 (24%) | 1 (11%) | 21 (18%) | 0 | 0 | |
| MLL rearrangement | 25 (93%) | 289 (78%) | 16 (94%) | 187 (76%) | 8 (89%) | 98 (82%) | 1 | 4 | |
| t(4;11) | 12 (48%) | 154 (53%) | 8 (50%) | 101 (54%) | 3 (38%) | 50 (51%) | 1 | 3 | |
| t(9;11) | 1 (4%) | 34 (12%) | 1 (6%) | 25 (13%) | 0 | 8 (8%) | 0 | 1 | |
| t(11;19) | 8 (32%) | 56 (19%) | 5 (31%) | 34 (18%) | 3 (38%) | 22 (22%) | 0 | 0 | |
| Other fusion partner‡ | 2 (8%) | 23 (8%) | 2 (13%) | 12 (6%) | 0 | 11 (11%) | 0 | 0 | |
| Fusion partner undefined | 2 (8%) | 22 (8%) | 0 | 15 (8%) | 2 (25%) | 7 (7%) | 0 | 0 | |
| CNS involvement | .48 | ||||||||
| Yes | 3 (10%) | 41 (11%) | 1 (8%) | 25 (9%) | 1 (13%) | 14 (12%) | 1 | 2 | |
| No | 18 (90%) | 347 (89%) | 11 (92%) | 244 (91%) | 7 (88%) | 102 (88%) | 0 | 1 | |
| Not evaluable or not known | 9 | 64 | 5 | 38 | 4 | 31 | 0 | 3 | |
| Response to 7-day prednisone prophase | .29 | ||||||||
| Good response | 17 (61%) | 301 (70%) | 16 (100%) | 300 (100%) | 1 (8%) | 1 (1%) | 0 | 0 | |
| Poor response | 11 (39%) | 127 (30%) | 0 | 0 | 11 (92%) | 127 (99%) | 0 | 0 | |
| Not evaluable | 0 | 6 | 0 | 2 | 0 | 4 | 0 | 0 | |
| Not known | 2 | 18 | 1 | 5 | 0 | 7 | 1 | 6 | |
All data are number (%). Percentages calculated as proportion of the known and evaluable data.
AUL indicates acute undifferentiated leukemia; MLL, mixed lineage leukemia; and CNS, central nervous system.
Comparison (Fisher exact test) between congenital ALL patients and ALL patients aged 1-12 months.
Value of P for association between age group and presence of MLL rearrangement. For MLL rearranged patients, distribution of translocation did not differ significantly (P = .53) between age groups.
The fusion partner of the MLL gene is defined, but differs from that in t(4;11), t(9;11), or t(11;19).